Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 88 entries
Sorted by: Best Match Show Resources per page
ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review.

Critical reviews in oncology/hematology

Beets G, Sebag-Montefiore D, Andritsch E, Arnold D, Beishon M, Crul M, Dekker JW, Delgado Bolton R, Fléjou JF, Grisold W, Henning G, Laghi A, Lovey J, Negrouk A, Pereira P, Roca P, Saarto T, Seufferlein T, Taylor C, Ugolini G, Velde CV, Herck BV, Yared W, Costa A, Naredi P.
PMID: 28109408
Crit Rev Oncol Hematol. 2017 Feb;110:81-93. doi: 10.1016/j.critrevonc.2016.12.001. Epub 2016 Dec 08.

BACKGROUND: ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to patients who have a specific tumour type. They are written by European experts representing...

Cite
Beets G, Sebag-Montefiore D, Andritsch E, et al. ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. Crit Rev Oncol Hematol. 2016;110:81-93doi: 10.1016/j.critrevonc.2016.12.001.
Beets, G., Sebag-Montefiore, D., Andritsch, E., Arnold, D., Beishon, M., Crul, M., Dekker, J. W., Delgado Bolton, R., Fléjou, J. F., Grisold, W., Henning, G., Laghi, A., Lovey, J., Negrouk, A., Pereira, P., Roca, P., Saarto, T., Seufferlein, T., Taylor, C., Ugolini, G., Velde, C. V., Herck, B. V., Yared, W., Costa, A., & Naredi, P. (2017). ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. Critical reviews in oncology/hematology, 11081-93. https://doi.org/10.1016/j.critrevonc.2016.12.001
Beets, Geerard, et al. "ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review." Critical reviews in oncology/hematology vol. 110 (2017): 81-93. doi: https://doi.org/10.1016/j.critrevonc.2016.12.001
Beets G, Sebag-Montefiore D, Andritsch E, Arnold D, Beishon M, Crul M, Dekker JW, Delgado Bolton R, Fléjou JF, Grisold W, Henning G, Laghi A, Lovey J, Negrouk A, Pereira P, Roca P, Saarto T, Seufferlein T, Taylor C, Ugolini G, Velde CV, Herck BV, Yared W, Costa A, Naredi P. ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. Crit Rev Oncol Hematol. 2017 Feb;110:81-93. doi: 10.1016/j.critrevonc.2016.12.001. Epub 2016 Dec 08. PMID: 28109408.
Copy Download .nbib Format: NLM
NOD2 and inflammation: current insights.

Journal of inflammation research

Negroni A, Pierdomenico M, Cucchiara S, Stronati L.
PMID: 29483781
J Inflamm Res. 2018 Feb 12;11:49-60. doi: 10.2147/JIR.S137606. eCollection 2018.

The nucleotide-binding oligomerization domain (NOD) protein, NOD2, belonging to the intracellular NOD-like receptor family, detects conserved motifs in bacterial peptidoglycan and promotes their clearance through activation of a proinflammatory transcriptional program and other innate immune pathways, including autophagy and...

Cite
Negroni A, Pierdomenico M, Cucchiara S, et al. NOD2 and inflammation: current insights. J Inflamm Res. 2018;11:49-60doi: 10.2147/JIR.S137606.
Negroni, A., Pierdomenico, M., Cucchiara, S., & Stronati, L. (2018). NOD2 and inflammation: current insights. Journal of inflammation research, 1149-60. https://doi.org/10.2147/JIR.S137606
Negroni, Anna, et al. "NOD2 and inflammation: current insights." Journal of inflammation research vol. 11 (2018): 49-60. doi: https://doi.org/10.2147/JIR.S137606
Negroni A, Pierdomenico M, Cucchiara S, Stronati L. NOD2 and inflammation: current insights. J Inflamm Res. 2018 Feb 12;11:49-60. doi: 10.2147/JIR.S137606. eCollection 2018. PMID: 29483781; PMCID: PMC5813767.
Copy Download .nbib Format: NLM
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.

ESMO open

Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA.
PMID: 29021919
ESMO Open. 2017 Aug 03;2(3):e000187. doi: 10.1136/esmoopen-2017-000187. eCollection 2017.

Cancer is a complex disease that is constantly evolving. It is now the most common cause of death in Europe after cardiovascular diseases. There are inequalities among European countries, potentially unsustainable healthcare systems impacting quality of cancer care and...

Cite
Negrouk A, Lacombe D, Cardoso F, et al. Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. ESMO Open. 2017;2(3):e000187doi: 10.1136/esmoopen-2017-000187.
Negrouk, A., Lacombe, D., Cardoso, F., Morin, F., Carrasco, E., Maurel, J., Maibach, R., Aranda, E., Marais, R., & Stahel, R. A. (2017). Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. ESMO open, 2(3), e000187. https://doi.org/10.1136/esmoopen-2017-000187
Negrouk, Anastassia, et al. "Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients." ESMO open vol. 2,3 (2017): e000187. doi: https://doi.org/10.1136/esmoopen-2017-000187
Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA. Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. ESMO Open. 2017 Aug 03;2(3):e000187. doi: 10.1136/esmoopen-2017-000187. eCollection 2017. PMID: 29021919; PMCID: PMC5634488.
Copy Download .nbib Format: NLM
Reversible posterior leukoencephalopathy associated with postpartum HELLP syndrome.

European journal of internal medicine

Negro A, Zuccoli G, Regolisti G, Mastrangeli S, Rossi E.
PMID: 16084357
Eur J Intern Med. 2005 Aug;16(4):291-3. doi: 10.1016/j.ejim.2004.11.010.

We describe a case of a severe, immediate postpartum HELLP syndrome (hemolysis, elevated liver enzyme levels, low platelet count) with reversible posterior leukoencephalopathy (RPLS) characterized by generalized seizure, altered mental status, and visual loss in a 37-year-old primigravid woman....

Cite
Negro A, Zuccoli G, Regolisti G, et al. Reversible posterior leukoencephalopathy associated with postpartum HELLP syndrome. Eur J Intern Med. 2005;16(4):291-3doi: 10.1016/j.ejim.2004.11.010.
Negro, A., Zuccoli, G., Regolisti, G., Mastrangeli, S., & Rossi, E. (2005). Reversible posterior leukoencephalopathy associated with postpartum HELLP syndrome. European journal of internal medicine, 16(4), 291-3. https://doi.org/10.1016/j.ejim.2004.11.010
Negro, Aurelio, et al. "Reversible posterior leukoencephalopathy associated with postpartum HELLP syndrome." European journal of internal medicine vol. 16,4 (2005): 291-3. doi: https://doi.org/10.1016/j.ejim.2004.11.010
Negro A, Zuccoli G, Regolisti G, Mastrangeli S, Rossi E. Reversible posterior leukoencephalopathy associated with postpartum HELLP syndrome. Eur J Intern Med. 2005 Aug;16(4):291-3. doi: 10.1016/j.ejim.2004.11.010. PMID: 16084357.
Copy Download .nbib Format: NLM
International rare cancers initiative.

The Lancet. Oncology

Keat N, Law K, Seymour M, Welch J, Trimble T, Lascombe D, Negrouk A.
PMID: 23369681
Lancet Oncol. 2013 Feb;14(2):109-10. doi: 10.1016/S1470-2045(12)70570-3.

No abstract available.

Cite
Keat N, Law K, Seymour M, et al. International rare cancers initiative. Lancet Oncol. 2013;14(2):109-10doi: 10.1016/S1470-2045(12)70570-3.
Keat, N., Law, K., Seymour, M., Welch, J., Trimble, T., Lascombe, D., & Negrouk, A. (2013). International rare cancers initiative. The Lancet. Oncology, 14(2), 109-10. https://doi.org/10.1016/S1470-2045(12)70570-3
Keat, Nicola, et al. "International rare cancers initiative." The Lancet. Oncology vol. 14,2 (2013): 109-10. doi: https://doi.org/10.1016/S1470-2045(12)70570-3
Keat N, Law K, Seymour M, Welch J, Trimble T, Lascombe D, Negrouk A. International rare cancers initiative. Lancet Oncol. 2013 Feb;14(2):109-10. doi: 10.1016/S1470-2045(12)70570-3. PMID: 23369681.
Copy Download .nbib Format: NLM
Mitochondrial Genome Sequence of the Legume Vicia faba.

Frontiers in plant science

Negruk V.
PMID: 23675376
Front Plant Sci. 2013 May 07;4:128. doi: 10.3389/fpls.2013.00128. eCollection 2013.

The number of plant mitochondrial genomes sequenced exceeds two dozen. However, for a detailed comparative study of different phylogenetic branches more plant mitochondrial genomes should be sequenced. This article presents sequencing data and comparative analysis of mitochondrial DNA (mtDNA)...

Cite
Negruk V. Mitochondrial Genome Sequence of the Legume Vicia faba. Front Plant Sci. 2013;4:128doi: 10.3389/fpls.2013.00128.
Negruk, V. (2013). Mitochondrial Genome Sequence of the Legume Vicia faba. Frontiers in plant science, 4128. https://doi.org/10.3389/fpls.2013.00128
Negruk, Valentine. "Mitochondrial Genome Sequence of the Legume Vicia faba." Frontiers in plant science vol. 4 (2013): 128. doi: https://doi.org/10.3389/fpls.2013.00128
Negruk V. Mitochondrial Genome Sequence of the Legume Vicia faba. Front Plant Sci. 2013 May 07;4:128. doi: 10.3389/fpls.2013.00128. eCollection 2013. PMID: 23675376; PMCID: PMC3646248.
Copy Download .nbib Format: NLM
Deciphering the task of N-acetyl aspartate in migraine.

Expert review of neurotherapeutics

Lionetto L, Capi M, Vignaroli G, Negro A, Martelletti P.
PMID: 23039385
Expert Rev Neurother. 2012 Sep;12(9):1057-9. doi: 10.1586/ern.12.97.

Migraine is a common neurological disorder producing significant personal and societal burden. In the evaluated study, serum concentrations of N-acetyl aspartate (NAA), a biomarker of neuronal integrity, was found to be decreased in patients suffering from migraine with aura....

Cite
Lionetto L, Capi M, Vignaroli G, et al. Deciphering the task of N-acetyl aspartate in migraine. Expert Rev Neurother. 2012;12(9):1057-9doi: 10.1586/ern.12.97.
Lionetto, L., Capi, M., Vignaroli, G., Negro, A., & Martelletti, P. (2012). Deciphering the task of N-acetyl aspartate in migraine. Expert review of neurotherapeutics, 12(9), 1057-9. https://doi.org/10.1586/ern.12.97
Lionetto, Luana, et al. "Deciphering the task of N-acetyl aspartate in migraine." Expert review of neurotherapeutics vol. 12,9 (2012): 1057-9. doi: https://doi.org/10.1586/ern.12.97
Lionetto L, Capi M, Vignaroli G, Negro A, Martelletti P. Deciphering the task of N-acetyl aspartate in migraine. Expert Rev Neurother. 2012 Sep;12(9):1057-9. doi: 10.1586/ern.12.97. PMID: 23039385.
Copy Download .nbib Format: NLM
Interspersed repetitive L1 family is differentially transcribed during the murine thymus ontogeny.

Cytotechnology

Raschellà G, Mosiello LF, Negroni A, Adorini L, Romeo A.
PMID: 22358443
Cytotechnology. 1987 Oct;1(1):65-71. doi: 10.1007/BF00351125.

Repetitive L1 family in the first LINE (Long Interspersed Element) found in mammals. Structural and evolutionary studies demonstrated the capability of this family to play a functional role and several examples of L1 transcription have been reported in humans...

Cite
Raschellà G, Mosiello LF, Negroni A, et al. Interspersed repetitive L1 family is differentially transcribed during the murine thymus ontogeny. Cytotechnology. 1987;1(1):65-71doi: 10.1007/BF00351125.
Raschellà, G., Mosiello, L. F., Negroni, A., Adorini, L., & Romeo, A. (1987). Interspersed repetitive L1 family is differentially transcribed during the murine thymus ontogeny. Cytotechnology, 1(1), 65-71. https://doi.org/10.1007/BF00351125
Raschellà, G, et al. "Interspersed repetitive L1 family is differentially transcribed during the murine thymus ontogeny." Cytotechnology vol. 1,1 (1987): 65-71. doi: https://doi.org/10.1007/BF00351125
Raschellà G, Mosiello LF, Negroni A, Adorini L, Romeo A. Interspersed repetitive L1 family is differentially transcribed during the murine thymus ontogeny. Cytotechnology. 1987 Oct;1(1):65-71. doi: 10.1007/BF00351125. PMID: 22358443.
Copy Download .nbib Format: NLM
Correction to: A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches.

The journal of headache and pain

García-Azorin D, Yamani N, Messina LM, Peeters I, Ferilli MAN, Ovchinnikov D, Speranza ML, Marini V, Negro A, Benemei S, Barloese M.
PMID: 30760196
J Headache Pain. 2019 Feb 13;20(1):14. doi: 10.1186/s10194-019-0967-2.

Following publication of the original article [1], we have been notified that the name of author five was spelled incorrectly as M. Ferrili, when the correct spelling is MAN Ferilli.

Cite
García-Azorin D, Yamani N, Messina LM, et al. Correction to: A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches. J Headache Pain. 2019;20(1):14doi: 10.1186/s10194-019-0967-2.
García-Azorin, D., Yamani, N., Messina, L. M., Peeters, I., Ferilli, M. A. N., Ovchinnikov, D., Speranza, M. L., Marini, V., Negro, A., Benemei, S., Barloese, M. (2019). Correction to: A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches. The journal of headache and pain, 20(1), 14. https://doi.org/10.1186/s10194-019-0967-2
García-Azorin, D, et al. "Correction to: A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches." The journal of headache and pain vol. 20,1 (2019): 14. doi: https://doi.org/10.1186/s10194-019-0967-2
García-Azorin D, Yamani N, Messina LM, Peeters I, Ferilli MAN, Ovchinnikov D, Speranza ML, Marini V, Negro A, Benemei S, Barloese M. Correction to: A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches. J Headache Pain. 2019 Feb 13;20(1):14. doi: 10.1186/s10194-019-0967-2. PMID: 30760196; PMCID: PMC6734367.
Copy Download .nbib Format: NLM
A Critical Evaluation on MOH Current Treatments.

Current treatment options in neurology

Negro A, Curto M, Lionetto L, Guerzoni S, Pini LA, Martelletti P.
PMID: 28808924
Curr Treat Options Neurol. 2017 Aug 15;19(9):32. doi: 10.1007/s11940-017-0465-2.

OPINION STATEMENT: Migraine is the most frequent neurological disorder observed in clinical practice characterized by moderate to severe pain attacks associated with neurological, gastrointestinal, and dysautonomic symptoms. Each year, 2.5% of patients with episodic migraine develop chronic migraine (CM)....

Cite
Negro A, Curto M, Lionetto L, et al. A Critical Evaluation on MOH Current Treatments. Curr Treat Options Neurol. 2017;19(9):32doi: 10.1007/s11940-017-0465-2.
Negro, A., Curto, M., Lionetto, L., Guerzoni, S., Pini, L. A., & Martelletti, P. (2017). A Critical Evaluation on MOH Current Treatments. Current treatment options in neurology, 19(9), 32. https://doi.org/10.1007/s11940-017-0465-2
Negro, Andrea, et al. "A Critical Evaluation on MOH Current Treatments." Current treatment options in neurology vol. 19,9 (2017): 32. doi: https://doi.org/10.1007/s11940-017-0465-2
Negro A, Curto M, Lionetto L, Guerzoni S, Pini LA, Martelletti P. A Critical Evaluation on MOH Current Treatments. Curr Treat Options Neurol. 2017 Aug 15;19(9):32. doi: 10.1007/s11940-017-0465-2. PMID: 28808924.
Copy Download .nbib Format: NLM
Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.

Journal of pain research

Negro A, Koverech A, Martelletti P.
PMID: 29563831
J Pain Res. 2018 Mar 08;11:515-526. doi: 10.2147/JPR.S132833. eCollection 2018.

Migraine is an important socioeconomic burden and is ranked the sixth cause of years of life lost because of disability in the general population and the third cause of years of life lost in people younger than 50 years....

Cite
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515-526doi: 10.2147/JPR.S132833.
Negro, A., Koverech, A., & Martelletti, P. (2018). Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. Journal of pain research, 11515-526. https://doi.org/10.2147/JPR.S132833
Negro, Andrea, et al. "Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential." Journal of pain research vol. 11 (2018): 515-526. doi: https://doi.org/10.2147/JPR.S132833
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018 Mar 08;11:515-526. doi: 10.2147/JPR.S132833. eCollection 2018. PMID: 29563831; PMCID: PMC5848843.
Copy Download .nbib Format: NLM
Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership.

Japanese journal of clinical oncology

Kataoka K, Nakamura K, Caballero C, Evrard S, Negrouk A, Shiozawa M, Collette L, Fukuda H, Lacombe D.
PMID: 28173055
Jpn J Clin Oncol. 2017 Feb 20;47(2):164-169. doi: 10.1093/jjco/hyw159.

The demand for international collaboration in cancer clinical trials has grown stronger to maximize efficiency, avoid duplication of effort and to achieve effective implementation of research results into medical practice. Infrastructures that could facilitate intercontinental collaboration not only between...

Cite
Kataoka K, Nakamura K, Caballero C, et al. Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership. Jpn J Clin Oncol. 2017;47(2):164-169doi: 10.1093/jjco/hyw159.
Kataoka, K., Nakamura, K., Caballero, C., Evrard, S., Negrouk, A., Shiozawa, M., Collette, L., Fukuda, H., & Lacombe, D. (2017). Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership. Japanese journal of clinical oncology, 47(2), 164-169. https://doi.org/10.1093/jjco/hyw159
Kataoka, Kozo, et al. "Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership." Japanese journal of clinical oncology vol. 47,2 (2017): 164-169. doi: https://doi.org/10.1093/jjco/hyw159
Kataoka K, Nakamura K, Caballero C, Evrard S, Negrouk A, Shiozawa M, Collette L, Fukuda H, Lacombe D. Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership. Jpn J Clin Oncol. 2017 Feb 20;47(2):164-169. doi: 10.1093/jjco/hyw159. PMID: 28173055.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 88 entries